Abstract
BACKGROUND
Severity of spasticity in multiple sclerosis (MS) directly correlates with the level and cost of care required. This study assessed whether a tetrahydrocannabinol/cannabidiol (THC/CBD) oromucosal spray for treatment of moderate-severe MS spasticity is a cost-effective use of healthcare resources in Wales.
METHODS
A Markov model was developed to compare THC/CBD plus standard of care (SoC) treatments with SoC alone.
RESULTS
At 30 years, total incremental cost for THC/CBD plus SoC treatment was estimated at £3,836/patient (ICER: £10,891/quality-adjusted life year [QALY]). Hospital admission costs had the greatest effect on the base case ICER. Inclusion of carer cost led to incremental cost of -£33,609/patient (ICER: -£95,423/QALY).
CONCLUSIONS
The THC/CBD spray was found to be cost-effective for the treatment of spasticity in MS, and dominant, if home carer costs were included. Use of THC/CBD has the potential to generate cost savings by significantly improving the symptoms of moderate to severe MS spasticity.
TY - JOUR
T1 - A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis.
AU - Gras,Adrien,
AU - Broughton,Julie,
Y1 - 2016/02/26/
PY - 2016/1/12/pubmed
PY - 2017/3/14/medline
PY - 2016/1/12/entrez
KW - Multiple sclerosis
KW - pharmacoeconomics
KW - resource utilization
KW - spasticity
KW - tetrahydrocannabinol/cannabidiol (THC/CBD) oromucosal spray
KW - treatment costs
SP - 771
EP - 779
JF - Expert review of pharmacoeconomics & outcomes research
JO - Expert Rev Pharmacoecon Outcomes Res
VL - 16
IS - 6
N2 - BACKGROUND: Severity of spasticity in multiple sclerosis (MS) directly correlates with the level and cost of care required. This study assessed whether a tetrahydrocannabinol/cannabidiol (THC/CBD) oromucosal spray for treatment of moderate-severe MS spasticity is a cost-effective use of healthcare resources in Wales. METHODS: A Markov model was developed to compare THC/CBD plus standard of care (SoC) treatments with SoC alone. RESULTS: At 30 years, total incremental cost for THC/CBD plus SoC treatment was estimated at £3,836/patient (ICER: £10,891/quality-adjusted life year [QALY]). Hospital admission costs had the greatest effect on the base case ICER. Inclusion of carer cost led to incremental cost of -£33,609/patient (ICER: -£95,423/QALY). CONCLUSIONS: The THC/CBD spray was found to be cost-effective for the treatment of spasticity in MS, and dominant, if home carer costs were included. Use of THC/CBD has the potential to generate cost savings by significantly improving the symptoms of moderate to severe MS spasticity.
SN - 1744-8379
UR - https://www.unboundmedicine.com/medline/citation/26750641/A_cost_effectiveness_model_for_the_use_of_a_cannabis_derived_oromucosal_spray_for_the_treatment_of_spasticity_in_multiple_sclerosis_
L2 - https://www.tandfonline.com/doi/full/10.1586/14737167.2016.1140574
DB - PRIME
DP - Unbound Medicine
ER -